nodes	percent_of_prediction	percent_of_DWPC	metapath
Paricalcitol—UGT1A4—Arylamine metabolism—NAT2—urinary bladder cancer	0.023	0.061	CbGpPWpGaD
Paricalcitol—CYP24A1—prostate gland—urinary bladder cancer	0.0186	0.135	CbGeAlD
Paricalcitol—CYP24A1—seminal vesicle—urinary bladder cancer	0.0157	0.114	CbGeAlD
Paricalcitol—UGT1A4—Glucuronidation—UGT2B7—urinary bladder cancer	0.0146	0.0389	CbGpPWpGaD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.0143	0.0379	CbGpPWpGaD
Paricalcitol—UGT1A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0141	0.0374	CbGpPWpGaD
Paricalcitol—CYP24A1—renal system—urinary bladder cancer	0.0127	0.0917	CbGeAlD
Paricalcitol—UGT1A4—renal system—urinary bladder cancer	0.0127	0.0917	CbGeAlD
Paricalcitol—UGT1A4—Glucuronidation—UGT2B7—urinary bladder cancer	0.0119	0.0315	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0108	0.0286	CbGpPWpGaD
Paricalcitol—VDR—prostate gland—urinary bladder cancer	0.0102	0.0741	CbGeAlD
Paricalcitol—CYP24A1—female reproductive system—urinary bladder cancer	0.0101	0.0734	CbGeAlD
Paricalcitol—CYP3A4—urine—urinary bladder cancer	0.00952	0.069	CbGeAlD
Paricalcitol—CYP24A1—vagina—urinary bladder cancer	0.00917	0.0664	CbGeAlD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00904	0.024	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—KRT5—urinary bladder cancer	0.00775	0.0206	CbGpPWpGaD
Paricalcitol—VDR—epithelium—urinary bladder cancer	0.00751	0.0544	CbGeAlD
Paricalcitol—VDR—renal system—urinary bladder cancer	0.00697	0.0505	CbGeAlD
Paricalcitol—CYP24A1—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00685	0.0182	CbGpPWpGaD
Paricalcitol—VDR—urethra—urinary bladder cancer	0.00685	0.0496	CbGeAlD
Paricalcitol—CYP24A1—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00676	0.0179	CbGpPWpGaD
Paricalcitol—Calcipotriol—MPO—urinary bladder cancer	0.00594	1	CrCbGaD
Paricalcitol—VDR—female reproductive system—urinary bladder cancer	0.00558	0.0404	CbGeAlD
Paricalcitol—CYP24A1—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00555	0.0147	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTZ1—urinary bladder cancer	0.00516	0.0137	CbGpPWpGaD
Paricalcitol—VDR—vagina—urinary bladder cancer	0.00505	0.0366	CbGeAlD
Paricalcitol—CYP3A4—Codeine and Morphine Metabolism—UGT2B7—urinary bladder cancer	0.00495	0.0131	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTO2—urinary bladder cancer	0.00489	0.013	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—NAT1—urinary bladder cancer	0.00489	0.013	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—TP63—urinary bladder cancer	0.00469	0.0125	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00448	0.0119	CbGpPWpGaD
Paricalcitol—UGT1A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00442	0.0117	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—TP63—urinary bladder cancer	0.0042	0.0112	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—ESR2—urinary bladder cancer	0.00404	0.0107	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTZ1—urinary bladder cancer	0.00378	0.01	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00373	0.00989	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—IGFBP3—urinary bladder cancer	0.00369	0.00979	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTO2—urinary bladder cancer	0.00358	0.00951	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—NAT1—urinary bladder cancer	0.00358	0.00951	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00353	0.00938	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR2—urinary bladder cancer	0.00352	0.00935	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—IGFBP3—urinary bladder cancer	0.0033	0.00876	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—UGT2B7—urinary bladder cancer	0.00328	0.0087	CbGpPWpGaD
Paricalcitol—VDR—lymph node—urinary bladder cancer	0.00326	0.0237	CbGeAlD
Paricalcitol—CYP24A1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00323	0.00858	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—NCOR1—urinary bladder cancer	0.00312	0.00828	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00302	0.00802	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—UGT2B7—urinary bladder cancer	0.00299	0.00793	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00298	0.00791	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—CYP4B1—urinary bladder cancer	0.00295	0.00783	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00291	0.00772	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.0029	0.00771	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00286	0.0076	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—NAT1—urinary bladder cancer	0.00286	0.0076	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.00282	0.0075	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—JAG1—urinary bladder cancer	0.00282	0.00748	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR2—urinary bladder cancer	0.00278	0.00739	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—NAT2—urinary bladder cancer	0.00268	0.00712	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—NQO1—urinary bladder cancer	0.00268	0.00711	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—PPARG—urinary bladder cancer	0.00264	0.00701	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.00262	0.00695	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00259	0.00687	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00258	0.00686	CbGpPWpGaD
Paricalcitol—CYP24A1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00254	0.00675	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—ATM—urinary bladder cancer	0.00247	0.00656	CbGpPWpGaD
Paricalcitol—VDR—Ovarian Infertility Genes—CDK4—urinary bladder cancer	0.00246	0.00653	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.00236	0.00626	CbGpPWpGaD
Paricalcitol—CYP3A4—renal system—urinary bladder cancer	0.00233	0.0169	CbGeAlD
Paricalcitol—UGT1A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00233	0.00617	CbGpPWpGaD
Paricalcitol—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00229	0.00607	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—CREBBP—urinary bladder cancer	0.00226	0.006	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—HPGDS—urinary bladder cancer	0.00214	0.00569	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—ESR1—urinary bladder cancer	0.00213	0.00567	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00213	0.00565	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTT1—urinary bladder cancer	0.00208	0.00552	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—NAT2—urinary bladder cancer	0.00196	0.00521	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—TP63—urinary bladder cancer	0.00196	0.00521	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptors—PPARG—urinary bladder cancer	0.00195	0.00517	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00194	0.00514	CbGpPWpGaD
Paricalcitol—CYP3A4—female reproductive system—urinary bladder cancer	0.00187	0.0135	CbGeAlD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00185	0.00492	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—FAS—urinary bladder cancer	0.00184	0.00488	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—ATM—urinary bladder cancer	0.00182	0.00482	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—ESR1—urinary bladder cancer	0.00169	0.00448	CbGpPWpGaD
Paricalcitol—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00163	0.00432	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—NAT2—urinary bladder cancer	0.00157	0.00416	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—HPGDS—urinary bladder cancer	0.00157	0.00416	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00155	0.00411	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—IGFBP3—urinary bladder cancer	0.00154	0.00409	CbGpPWpGaD
Paricalcitol—VDR—Retinoic acid receptors-mediated signaling—EP300—urinary bladder cancer	0.00154	0.00409	CbGpPWpGaD
Paricalcitol—VDR—Nuclear Receptor transcription pathway—PPARG—urinary bladder cancer	0.00154	0.00409	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTT1—urinary bladder cancer	0.00152	0.00404	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—NCOR1—urinary bladder cancer	0.00148	0.00394	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTP1—urinary bladder cancer	0.00144	0.00383	CbGpPWpGaD
Paricalcitol—VDR—RXR and RAR heterodimerization with other nuclear receptor—TNF—urinary bladder cancer	0.0014	0.00372	CbGpPWpGaD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.0014	0.00372	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of deltaNp63 isoforms—CDKN2A—urinary bladder cancer	0.00138	0.00367	CbGpPWpGaD
Paricalcitol—UGT1A4—Phase II conjugation—GSTM1—urinary bladder cancer	0.00132	0.00352	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—HPGDS—urinary bladder cancer	0.00125	0.00333	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN2A—urinary bladder cancer	0.00124	0.00328	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTT1—urinary bladder cancer	0.00122	0.00323	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDK4—urinary bladder cancer	0.00117	0.00311	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—ESR1—urinary bladder cancer	0.00117	0.00309	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00116	0.00309	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—NQO1—urinary bladder cancer	0.00115	0.00306	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.00113	0.00301	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTP1—urinary bladder cancer	0.00105	0.0028	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.00104	0.00277	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00104	0.00276	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CREBBP—urinary bladder cancer	0.00102	0.00271	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.00101	0.00269	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—CDKN1A—urinary bladder cancer	0.00101	0.00268	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000998	0.00265	CbGpPWpGaD
Paricalcitol—CYP24A1—Biological oxidations—GSTM1—urinary bladder cancer	0.000969	0.00257	CbGpPWpGaD
Paricalcitol—VDR—Validated transcriptional targets of TAp63 isoforms—EP300—urinary bladder cancer	0.000962	0.00255	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GSTP1—urinary bladder cancer	0.000961	0.00255	CbGpPWpGaD
Paricalcitol—CYP24A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000956	0.00254	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—GPX1—urinary bladder cancer	0.000917	0.00243	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000889	0.00236	CbGpPWpGaD
Paricalcitol—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000889	0.00236	CbGpPWpGaD
Paricalcitol—UGT1A4—NRF2 pathway—GSTM1—urinary bladder cancer	0.000883	0.00235	CbGpPWpGaD
Paricalcitol—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000877	0.00233	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—FAS—urinary bladder cancer	0.000858	0.00228	CbGpPWpGaD
Paricalcitol—UGT1A4—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000847	0.00225	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000843	0.00224	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000831	0.00221	CbGpPWpGaD
Paricalcitol—UGT1A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000775	0.00206	CbGpPWpGaD
Paricalcitol—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000765	0.00203	CbGpPWpGaD
Paricalcitol—UGT1A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000764	0.00203	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—CDKN1A—urinary bladder cancer	0.000731	0.00194	CbGpPWpGaD
Paricalcitol—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00072	0.00191	CbGpPWpGaD
Paricalcitol—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000718	0.00191	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—EP300—urinary bladder cancer	0.000695	0.00185	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CREBBP—urinary bladder cancer	0.000659	0.00175	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—RB1—urinary bladder cancer	0.000657	0.00174	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTZ1—urinary bladder cancer	0.000646	0.00172	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—GSTO2—urinary bladder cancer	0.000612	0.00163	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NAT1—urinary bladder cancer	0.000612	0.00163	CbGpPWpGaD
Paricalcitol—VDR—Regulation of nuclear SMAD2/3 signaling—MYC—urinary bladder cancer	0.000606	0.00161	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000602	0.0016	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—UGT2B7—urinary bladder cancer	0.00056	0.00149	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTZ1—urinary bladder cancer	0.000516	0.00137	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CYP4B1—urinary bladder cancer	0.000504	0.00134	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.00049	0.0013	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTO2—urinary bladder cancer	0.00049	0.0013	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NAT1—urinary bladder cancer	0.00049	0.0013	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000483	0.00128	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—ESR2—urinary bladder cancer	0.00048	0.00128	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—SLC19A1—urinary bladder cancer	0.000476	0.00126	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—CDKN1A—urinary bladder cancer	0.000472	0.00125	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—PTEN—urinary bladder cancer	0.000471	0.00125	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.000465	0.00123	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.000465	0.00123	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PRSS3—urinary bladder cancer	0.000464	0.00123	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000458	0.00122	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—EP300—urinary bladder cancer	0.000449	0.00119	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—UGT2B7—urinary bladder cancer	0.000448	0.00119	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000425	0.00113	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000419	0.00111	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CYP4B1—urinary bladder cancer	0.000403	0.00107	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000383	0.00102	CbGpPWpGaD
Paricalcitol—VDR—Direct p53 effectors—EGFR—urinary bladder cancer	0.000383	0.00102	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—SLC19A1—urinary bladder cancer	0.000381	0.00101	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000377	0.001	CbGpPWpGaD
Paricalcitol—Nausea—Thiotepa—urinary bladder cancer	0.000373	0.000778	CcSEcCtD
Paricalcitol—Urethral disorder—Methotrexate—urinary bladder cancer	0.000373	0.000778	CcSEcCtD
Paricalcitol—Weight decreased—Doxorubicin—urinary bladder cancer	0.000372	0.000777	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000372	0.000988	CbGpPWpGaD
Paricalcitol—Sinusitis—Epirubicin—urinary bladder cancer	0.000372	0.000776	CcSEcCtD
Paricalcitol—Feeling abnormal—Etoposide—urinary bladder cancer	0.000372	0.000776	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—PRSS3—urinary bladder cancer	0.000371	0.000985	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—TYMP—urinary bladder cancer	0.000371	0.000985	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—NCOR1—urinary bladder cancer	0.000371	0.000985	CbGpPWpGaD
Paricalcitol—Pneumonia—Doxorubicin—urinary bladder cancer	0.000369	0.00077	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000369	0.00077	CcSEcCtD
Paricalcitol—Pruritus—Fluorouracil—urinary bladder cancer	0.000368	0.000767	CcSEcCtD
Paricalcitol—Infestation—Doxorubicin—urinary bladder cancer	0.000367	0.000765	CcSEcCtD
Paricalcitol—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000367	0.000765	CcSEcCtD
Paricalcitol—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000363	0.000757	CcSEcCtD
Paricalcitol—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000362	0.000754	CcSEcCtD
Paricalcitol—Urticaria—Etoposide—urinary bladder cancer	0.000358	0.000748	CcSEcCtD
Paricalcitol—Body temperature increased—Etoposide—urinary bladder cancer	0.000357	0.000744	CcSEcCtD
Paricalcitol—Abdominal pain—Etoposide—urinary bladder cancer	0.000357	0.000744	CcSEcCtD
Paricalcitol—Conjunctivitis—Doxorubicin—urinary bladder cancer	0.000357	0.000744	CcSEcCtD
Paricalcitol—Urinary tract infection—Doxorubicin—urinary bladder cancer	0.000357	0.000744	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000356	0.000946	CbGpPWpGaD
Paricalcitol—Eye disorder—Methotrexate—urinary bladder cancer	0.000356	0.000742	CcSEcCtD
Paricalcitol—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000355	0.000742	CcSEcCtD
Paricalcitol—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000354	0.000739	CcSEcCtD
Paricalcitol—Asthenia—Cisplatin—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Paricalcitol—Pharyngitis—Epirubicin—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Paricalcitol—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000353	0.000737	CcSEcCtD
Paricalcitol—Sweating—Doxorubicin—urinary bladder cancer	0.000352	0.000734	CcSEcCtD
Paricalcitol—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000352	0.000733	CcSEcCtD
Paricalcitol—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000351	0.000732	CcSEcCtD
Paricalcitol—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.00035	0.00073	CcSEcCtD
Paricalcitol—Urethral disorder—Epirubicin—urinary bladder cancer	0.000349	0.000728	CcSEcCtD
Paricalcitol—Epistaxis—Doxorubicin—urinary bladder cancer	0.000346	0.000722	CcSEcCtD
Paricalcitol—Angiopathy—Methotrexate—urinary bladder cancer	0.000345	0.00072	CcSEcCtD
Paricalcitol—Sinusitis—Doxorubicin—urinary bladder cancer	0.000344	0.000718	CcSEcCtD
Paricalcitol—Immune system disorder—Methotrexate—urinary bladder cancer	0.000344	0.000717	CcSEcCtD
Paricalcitol—Dizziness—Fluorouracil—urinary bladder cancer	0.000344	0.000717	CcSEcCtD
Paricalcitol—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000343	0.000715	CcSEcCtD
Paricalcitol—Chills—Methotrexate—urinary bladder cancer	0.000341	0.000712	CcSEcCtD
Paricalcitol—Diarrhoea—Cisplatin—urinary bladder cancer	0.000337	0.000703	CcSEcCtD
Paricalcitol—Alopecia—Methotrexate—urinary bladder cancer	0.000336	0.000701	CcSEcCtD
Paricalcitol—Vomiting—Gemcitabine—urinary bladder cancer	0.000336	0.000701	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—NAT2—urinary bladder cancer	0.000336	0.000891	CbGpPWpGaD
Paricalcitol—Mental disorder—Methotrexate—urinary bladder cancer	0.000333	0.000695	CcSEcCtD
Paricalcitol—Rash—Gemcitabine—urinary bladder cancer	0.000333	0.000695	CcSEcCtD
Paricalcitol—Dermatitis—Gemcitabine—urinary bladder cancer	0.000333	0.000694	CcSEcCtD
Paricalcitol—Eye disorder—Epirubicin—urinary bladder cancer	0.000333	0.000694	CcSEcCtD
Paricalcitol—Hypersensitivity—Etoposide—urinary bladder cancer	0.000332	0.000694	CcSEcCtD
Paricalcitol—Malnutrition—Methotrexate—urinary bladder cancer	0.000331	0.000691	CcSEcCtD
Paricalcitol—Headache—Gemcitabine—urinary bladder cancer	0.000331	0.000691	CcSEcCtD
Paricalcitol—Cardiac disorder—Epirubicin—urinary bladder cancer	0.00033	0.000689	CcSEcCtD
Paricalcitol—Vomiting—Fluorouracil—urinary bladder cancer	0.00033	0.000689	CcSEcCtD
Paricalcitol—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.00033	0.000875	CbGpPWpGaD
Paricalcitol—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000328	0.000684	CcSEcCtD
Paricalcitol—Rash—Fluorouracil—urinary bladder cancer	0.000328	0.000683	CcSEcCtD
Paricalcitol—Dermatitis—Fluorouracil—urinary bladder cancer	0.000327	0.000683	CcSEcCtD
Paricalcitol—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000327	0.000682	CcSEcCtD
Paricalcitol—Headache—Fluorouracil—urinary bladder cancer	0.000325	0.000679	CcSEcCtD
Paricalcitol—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000325	0.000679	CcSEcCtD
Paricalcitol—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000325	0.000677	CcSEcCtD
Paricalcitol—Dysgeusia—Methotrexate—urinary bladder cancer	0.000324	0.000677	CcSEcCtD
Paricalcitol—Asthenia—Etoposide—urinary bladder cancer	0.000324	0.000675	CcSEcCtD
Paricalcitol—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000324	0.000675	CcSEcCtD
Paricalcitol—Angiopathy—Epirubicin—urinary bladder cancer	0.000323	0.000674	CcSEcCtD
Paricalcitol—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000323	0.000674	CcSEcCtD
Paricalcitol—Immune system disorder—Epirubicin—urinary bladder cancer	0.000322	0.000671	CcSEcCtD
Paricalcitol—VDR—Direct p53 effectors—TP53—urinary bladder cancer	0.000321	0.000853	CbGpPWpGaD
Paricalcitol—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000321	0.000669	CcSEcCtD
Paricalcitol—Back pain—Methotrexate—urinary bladder cancer	0.00032	0.000668	CcSEcCtD
Paricalcitol—Chills—Epirubicin—urinary bladder cancer	0.000319	0.000666	CcSEcCtD
Paricalcitol—Pruritus—Etoposide—urinary bladder cancer	0.000319	0.000666	CcSEcCtD
Paricalcitol—Arrhythmia—Epirubicin—urinary bladder cancer	0.000318	0.000663	CcSEcCtD
Paricalcitol—Alopecia—Epirubicin—urinary bladder cancer	0.000315	0.000656	CcSEcCtD
Paricalcitol—Nausea—Gemcitabine—urinary bladder cancer	0.000314	0.000655	CcSEcCtD
Paricalcitol—Vomiting—Cisplatin—urinary bladder cancer	0.000313	0.000653	CcSEcCtD
Paricalcitol—Mental disorder—Epirubicin—urinary bladder cancer	0.000312	0.000651	CcSEcCtD
Paricalcitol—Rash—Cisplatin—urinary bladder cancer	0.000311	0.000648	CcSEcCtD
Paricalcitol—Dermatitis—Cisplatin—urinary bladder cancer	0.00031	0.000647	CcSEcCtD
Paricalcitol—Malnutrition—Epirubicin—urinary bladder cancer	0.00031	0.000647	CcSEcCtD
Paricalcitol—Diarrhoea—Etoposide—urinary bladder cancer	0.000309	0.000644	CcSEcCtD
Paricalcitol—Nausea—Fluorouracil—urinary bladder cancer	0.000309	0.000644	CcSEcCtD
Paricalcitol—Eye disorder—Doxorubicin—urinary bladder cancer	0.000308	0.000642	CcSEcCtD
Paricalcitol—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000307	0.000641	CcSEcCtD
Paricalcitol—Anaemia—Methotrexate—urinary bladder cancer	0.000306	0.000639	CcSEcCtD
Paricalcitol—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000306	0.000638	CcSEcCtD
Paricalcitol—Tension—Epirubicin—urinary bladder cancer	0.000304	0.000634	CcSEcCtD
Paricalcitol—Dysgeusia—Epirubicin—urinary bladder cancer	0.000304	0.000633	CcSEcCtD
Paricalcitol—Nervousness—Epirubicin—urinary bladder cancer	0.000301	0.000628	CcSEcCtD
Paricalcitol—Back pain—Epirubicin—urinary bladder cancer	0.0003	0.000625	CcSEcCtD
Paricalcitol—Angiopathy—Doxorubicin—urinary bladder cancer	0.000299	0.000623	CcSEcCtD
Paricalcitol—Malaise—Methotrexate—urinary bladder cancer	0.000299	0.000623	CcSEcCtD
Paricalcitol—Dizziness—Etoposide—urinary bladder cancer	0.000298	0.000622	CcSEcCtD
Paricalcitol—Muscle spasms—Epirubicin—urinary bladder cancer	0.000298	0.000622	CcSEcCtD
Paricalcitol—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000298	0.000621	CcSEcCtD
Paricalcitol—Vertigo—Methotrexate—urinary bladder cancer	0.000298	0.000621	CcSEcCtD
Paricalcitol—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000297	0.000619	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—TYMP—urinary bladder cancer	0.000297	0.000788	CbGpPWpGaD
Paricalcitol—Leukopenia—Methotrexate—urinary bladder cancer	0.000296	0.000618	CcSEcCtD
Paricalcitol—Chills—Doxorubicin—urinary bladder cancer	0.000296	0.000617	CcSEcCtD
Paricalcitol—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000294	0.000614	CcSEcCtD
Paricalcitol—Nausea—Cisplatin—urinary bladder cancer	0.000293	0.00061	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—ESR1—urinary bladder cancer	0.000291	0.000774	CbGpPWpGaD
Paricalcitol—Alopecia—Doxorubicin—urinary bladder cancer	0.000291	0.000607	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—RRM2—urinary bladder cancer	0.00029	0.000769	CbGpPWpGaD
Paricalcitol—Cough—Methotrexate—urinary bladder cancer	0.000289	0.000603	CcSEcCtD
Paricalcitol—Mental disorder—Doxorubicin—urinary bladder cancer	0.000289	0.000602	CcSEcCtD
Paricalcitol—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000288	0.0006	CcSEcCtD
Paricalcitol—Vomiting—Etoposide—urinary bladder cancer	0.000287	0.000598	CcSEcCtD
Paricalcitol—Malnutrition—Doxorubicin—urinary bladder cancer	0.000287	0.000598	CcSEcCtD
Paricalcitol—Anaemia—Epirubicin—urinary bladder cancer	0.000286	0.000598	CcSEcCtD
Paricalcitol—Agitation—Epirubicin—urinary bladder cancer	0.000285	0.000594	CcSEcCtD
Paricalcitol—Rash—Etoposide—urinary bladder cancer	0.000285	0.000593	CcSEcCtD
Paricalcitol—Dermatitis—Etoposide—urinary bladder cancer	0.000284	0.000593	CcSEcCtD
Paricalcitol—Headache—Etoposide—urinary bladder cancer	0.000283	0.00059	CcSEcCtD
Paricalcitol—Chest pain—Methotrexate—urinary bladder cancer	0.000282	0.000588	CcSEcCtD
Paricalcitol—Myalgia—Methotrexate—urinary bladder cancer	0.000282	0.000588	CcSEcCtD
Paricalcitol—Arthralgia—Methotrexate—urinary bladder cancer	0.000282	0.000588	CcSEcCtD
Paricalcitol—Tension—Doxorubicin—urinary bladder cancer	0.000281	0.000587	CcSEcCtD
Paricalcitol—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000281	0.000586	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.00028	0.000584	CcSEcCtD
Paricalcitol—Malaise—Epirubicin—urinary bladder cancer	0.000279	0.000583	CcSEcCtD
Paricalcitol—Discomfort—Methotrexate—urinary bladder cancer	0.000279	0.000581	CcSEcCtD
Paricalcitol—Nervousness—Doxorubicin—urinary bladder cancer	0.000279	0.000581	CcSEcCtD
Paricalcitol—Vertigo—Epirubicin—urinary bladder cancer	0.000278	0.000581	CcSEcCtD
Paricalcitol—Syncope—Epirubicin—urinary bladder cancer	0.000278	0.00058	CcSEcCtD
Paricalcitol—Leukopenia—Epirubicin—urinary bladder cancer	0.000277	0.000579	CcSEcCtD
Paricalcitol—Back pain—Doxorubicin—urinary bladder cancer	0.000277	0.000579	CcSEcCtD
Paricalcitol—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000276	0.000575	CcSEcCtD
Paricalcitol—Palpitations—Epirubicin—urinary bladder cancer	0.000274	0.000571	CcSEcCtD
Paricalcitol—Confusional state—Methotrexate—urinary bladder cancer	0.000273	0.000569	CcSEcCtD
Paricalcitol—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000272	0.000568	CcSEcCtD
Paricalcitol—Cough—Epirubicin—urinary bladder cancer	0.00027	0.000564	CcSEcCtD
Paricalcitol—Infection—Methotrexate—urinary bladder cancer	0.000269	0.00056	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—HPGDS—urinary bladder cancer	0.000268	0.000712	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—ENO2—urinary bladder cancer	0.000268	0.000712	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NAT2—urinary bladder cancer	0.000268	0.000712	CbGpPWpGaD
Paricalcitol—Nausea—Etoposide—urinary bladder cancer	0.000268	0.000559	CcSEcCtD
Paricalcitol—Hypertension—Epirubicin—urinary bladder cancer	0.000268	0.000558	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000267	0.000708	CbGpPWpGaD
Paricalcitol—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000266	0.000555	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—PPARG—urinary bladder cancer	0.000266	0.000706	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—SMC1A—urinary bladder cancer	0.000265	0.000705	CbGpPWpGaD
Paricalcitol—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000265	0.000553	CcSEcCtD
Paricalcitol—Anaemia—Doxorubicin—urinary bladder cancer	0.000265	0.000553	CcSEcCtD
Paricalcitol—Chest pain—Epirubicin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Paricalcitol—Myalgia—Epirubicin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Paricalcitol—Arthralgia—Epirubicin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Paricalcitol—Agitation—Doxorubicin—urinary bladder cancer	0.000264	0.00055	CcSEcCtD
Paricalcitol—Anxiety—Epirubicin—urinary bladder cancer	0.000263	0.000549	CcSEcCtD
Paricalcitol—Skin disorder—Methotrexate—urinary bladder cancer	0.000263	0.000548	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000262	0.000547	CcSEcCtD
Paricalcitol—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000261	0.000545	CcSEcCtD
Paricalcitol—Discomfort—Epirubicin—urinary bladder cancer	0.000261	0.000544	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GSTT1—urinary bladder cancer	0.00026	0.000691	CbGpPWpGaD
Paricalcitol—Malaise—Doxorubicin—urinary bladder cancer	0.000259	0.000539	CcSEcCtD
Paricalcitol—Dry mouth—Epirubicin—urinary bladder cancer	0.000258	0.000538	CcSEcCtD
Paricalcitol—Vertigo—Doxorubicin—urinary bladder cancer	0.000258	0.000537	CcSEcCtD
Paricalcitol—Anorexia—Methotrexate—urinary bladder cancer	0.000258	0.000537	CcSEcCtD
Paricalcitol—Syncope—Doxorubicin—urinary bladder cancer	0.000257	0.000536	CcSEcCtD
Paricalcitol—Leukopenia—Doxorubicin—urinary bladder cancer	0.000257	0.000535	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	0.000256	0.00068	CbGpPWpGaD
Paricalcitol—VDR—Generic Transcription Pathway—CREBBP—urinary bladder cancer	0.000255	0.000678	CbGpPWpGaD
Paricalcitol—Confusional state—Epirubicin—urinary bladder cancer	0.000255	0.000532	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000255	0.000676	CbGpPWpGaD
Paricalcitol—Palpitations—Doxorubicin—urinary bladder cancer	0.000253	0.000529	CcSEcCtD
Paricalcitol—Oedema—Epirubicin—urinary bladder cancer	0.000253	0.000528	CcSEcCtD
Paricalcitol—Hypotension—Methotrexate—urinary bladder cancer	0.000253	0.000527	CcSEcCtD
Paricalcitol—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000252	0.000526	CcSEcCtD
Paricalcitol—Infection—Epirubicin—urinary bladder cancer	0.000251	0.000524	CcSEcCtD
Paricalcitol—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000251	0.000667	CbGpPWpGaD
Paricalcitol—Cough—Doxorubicin—urinary bladder cancer	0.00025	0.000522	CcSEcCtD
Paricalcitol—Shock—Epirubicin—urinary bladder cancer	0.000249	0.000519	CcSEcCtD
Paricalcitol—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000248	0.000517	CcSEcCtD
Paricalcitol—Hypertension—Doxorubicin—urinary bladder cancer	0.000248	0.000516	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000246	0.000514	CcSEcCtD
Paricalcitol—Skin disorder—Epirubicin—urinary bladder cancer	0.000246	0.000513	CcSEcCtD
Paricalcitol—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000245	0.00051	CcSEcCtD
Paricalcitol—Insomnia—Methotrexate—urinary bladder cancer	0.000244	0.00051	CcSEcCtD
Paricalcitol—Myalgia—Doxorubicin—urinary bladder cancer	0.000244	0.000509	CcSEcCtD
Paricalcitol—Chest pain—Doxorubicin—urinary bladder cancer	0.000244	0.000509	CcSEcCtD
Paricalcitol—Arthralgia—Doxorubicin—urinary bladder cancer	0.000244	0.000509	CcSEcCtD
Paricalcitol—Anxiety—Doxorubicin—urinary bladder cancer	0.000243	0.000508	CcSEcCtD
Paricalcitol—Paraesthesia—Methotrexate—urinary bladder cancer	0.000243	0.000506	CcSEcCtD
Paricalcitol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000242	0.000506	CcSEcCtD
Paricalcitol—Discomfort—Doxorubicin—urinary bladder cancer	0.000241	0.000503	CcSEcCtD
Paricalcitol—Anorexia—Epirubicin—urinary bladder cancer	0.000241	0.000503	CcSEcCtD
Paricalcitol—Dyspnoea—Methotrexate—urinary bladder cancer	0.000241	0.000503	CcSEcCtD
Paricalcitol—Somnolence—Methotrexate—urinary bladder cancer	0.00024	0.000501	CcSEcCtD
Paricalcitol—Dry mouth—Doxorubicin—urinary bladder cancer	0.000239	0.000498	CcSEcCtD
Paricalcitol—Dyspepsia—Methotrexate—urinary bladder cancer	0.000238	0.000496	CcSEcCtD
Paricalcitol—Hypotension—Epirubicin—urinary bladder cancer	0.000236	0.000493	CcSEcCtD
Paricalcitol—Confusional state—Doxorubicin—urinary bladder cancer	0.000236	0.000492	CcSEcCtD
Paricalcitol—Decreased appetite—Methotrexate—urinary bladder cancer	0.000235	0.00049	CcSEcCtD
Paricalcitol—Oedema—Doxorubicin—urinary bladder cancer	0.000234	0.000488	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000233	0.000487	CcSEcCtD
Paricalcitol—Fatigue—Methotrexate—urinary bladder cancer	0.000233	0.000486	CcSEcCtD
Paricalcitol—Infection—Doxorubicin—urinary bladder cancer	0.000233	0.000485	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—RRM2—urinary bladder cancer	0.000232	0.000615	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR2—urinary bladder cancer	0.000231	0.000614	CbGpPWpGaD
Paricalcitol—Pain—Methotrexate—urinary bladder cancer	0.000231	0.000482	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00023	0.000481	CcSEcCtD
Paricalcitol—Shock—Doxorubicin—urinary bladder cancer	0.00023	0.00048	CcSEcCtD
Paricalcitol—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.00023	0.000479	CcSEcCtD
Paricalcitol—Insomnia—Epirubicin—urinary bladder cancer	0.000229	0.000477	CcSEcCtD
Paricalcitol—Skin disorder—Doxorubicin—urinary bladder cancer	0.000227	0.000474	CcSEcCtD
Paricalcitol—Paraesthesia—Epirubicin—urinary bladder cancer	0.000227	0.000474	CcSEcCtD
Paricalcitol—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000226	0.000472	CcSEcCtD
Paricalcitol—Dyspnoea—Epirubicin—urinary bladder cancer	0.000226	0.00047	CcSEcCtD
Paricalcitol—Somnolence—Epirubicin—urinary bladder cancer	0.000225	0.000469	CcSEcCtD
Paricalcitol—Anorexia—Doxorubicin—urinary bladder cancer	0.000223	0.000465	CcSEcCtD
Paricalcitol—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000223	0.000465	CcSEcCtD
Paricalcitol—Dyspepsia—Epirubicin—urinary bladder cancer	0.000223	0.000464	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000221	0.000461	CcSEcCtD
Paricalcitol—Decreased appetite—Epirubicin—urinary bladder cancer	0.00022	0.000459	CcSEcCtD
Paricalcitol—Hypotension—Doxorubicin—urinary bladder cancer	0.000219	0.000456	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000218	0.000456	CcSEcCtD
Paricalcitol—Fatigue—Epirubicin—urinary bladder cancer	0.000218	0.000455	CcSEcCtD
Paricalcitol—Constipation—Epirubicin—urinary bladder cancer	0.000216	0.000451	CcSEcCtD
Paricalcitol—Pain—Epirubicin—urinary bladder cancer	0.000216	0.000451	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—NQO1—urinary bladder cancer	0.000216	0.000574	CbGpPWpGaD
Paricalcitol—Urticaria—Methotrexate—urinary bladder cancer	0.000215	0.000448	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—ENO2—urinary bladder cancer	0.000214	0.000569	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—HPGDS—urinary bladder cancer	0.000214	0.000569	CbGpPWpGaD
Paricalcitol—Abdominal pain—Methotrexate—urinary bladder cancer	0.000214	0.000446	CcSEcCtD
Paricalcitol—Body temperature increased—Methotrexate—urinary bladder cancer	0.000214	0.000446	CcSEcCtD
Paricalcitol—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000213	0.000445	CcSEcCtD
Paricalcitol—Insomnia—Doxorubicin—urinary bladder cancer	0.000212	0.000442	CcSEcCtD
Paricalcitol—Paraesthesia—Doxorubicin—urinary bladder cancer	0.00021	0.000438	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	0.00021	0.000557	CbGpPWpGaD
Paricalcitol—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000209	0.000435	CcSEcCtD
Paricalcitol—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000208	0.000435	CcSEcCtD
Paricalcitol—Somnolence—Doxorubicin—urinary bladder cancer	0.000208	0.000434	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—GSTT1—urinary bladder cancer	0.000208	0.000552	CbGpPWpGaD
Paricalcitol—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000207	0.000431	CcSEcCtD
Paricalcitol—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000206	0.00043	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000204	0.00054	CbGpPWpGaD
Paricalcitol—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000203	0.000424	CcSEcCtD
Paricalcitol—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000202	0.000421	CcSEcCtD
Paricalcitol—Fatigue—Doxorubicin—urinary bladder cancer	0.000202	0.000421	CcSEcCtD
Paricalcitol—Urticaria—Epirubicin—urinary bladder cancer	0.000201	0.000419	CcSEcCtD
Paricalcitol—Constipation—Doxorubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Paricalcitol—Pain—Doxorubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Paricalcitol—Body temperature increased—Epirubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Paricalcitol—Abdominal pain—Epirubicin—urinary bladder cancer	0.0002	0.000417	CcSEcCtD
Paricalcitol—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000199	0.000415	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000197	0.000524	CbGpPWpGaD
Paricalcitol—Asthenia—Methotrexate—urinary bladder cancer	0.000194	0.000405	CcSEcCtD
Paricalcitol—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000193	0.000402	CcSEcCtD
Paricalcitol—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000191	0.000399	CcSEcCtD
Paricalcitol—Pruritus—Methotrexate—urinary bladder cancer	0.000191	0.000399	CcSEcCtD
Paricalcitol—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000186	0.000389	CcSEcCtD
Paricalcitol—Urticaria—Doxorubicin—urinary bladder cancer	0.000186	0.000388	CcSEcCtD
Paricalcitol—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000185	0.000386	CcSEcCtD
Paricalcitol—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000185	0.000386	CcSEcCtD
Paricalcitol—Diarrhoea—Methotrexate—urinary bladder cancer	0.000185	0.000386	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	0.000183	0.000486	CbGpPWpGaD
Paricalcitol—Asthenia—Epirubicin—urinary bladder cancer	0.000181	0.000379	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GSTP1—urinary bladder cancer	0.00018	0.000479	CbGpPWpGaD
Paricalcitol—Pruritus—Epirubicin—urinary bladder cancer	0.000179	0.000373	CcSEcCtD
Paricalcitol—Dizziness—Methotrexate—urinary bladder cancer	0.000179	0.000373	CcSEcCtD
Paricalcitol—VDR—Gene Expression—NCOR1—urinary bladder cancer	0.000179	0.000474	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	0.000174	0.000463	CbGpPWpGaD
Paricalcitol—Diarrhoea—Epirubicin—urinary bladder cancer	0.000173	0.000361	CcSEcCtD
Paricalcitol—UGT1A4—Metabolism—NQO1—urinary bladder cancer	0.000173	0.000459	CbGpPWpGaD
Paricalcitol—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000172	0.00036	CcSEcCtD
Paricalcitol—Vomiting—Methotrexate—urinary bladder cancer	0.000172	0.000358	CcSEcCtD
Paricalcitol—Rash—Methotrexate—urinary bladder cancer	0.00017	0.000355	CcSEcCtD
Paricalcitol—Dermatitis—Methotrexate—urinary bladder cancer	0.00017	0.000355	CcSEcCtD
Paricalcitol—Headache—Methotrexate—urinary bladder cancer	0.000169	0.000353	CcSEcCtD
Paricalcitol—VDR—Gene Expression—ERCC2—urinary bladder cancer	0.000168	0.000446	CbGpPWpGaD
Paricalcitol—Asthenia—Doxorubicin—urinary bladder cancer	0.000168	0.00035	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—TYMS—urinary bladder cancer	0.000168	0.000445	CbGpPWpGaD
Paricalcitol—Dizziness—Epirubicin—urinary bladder cancer	0.000167	0.000349	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GSTM1—urinary bladder cancer	0.000166	0.00044	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—NCOR1—urinary bladder cancer	0.000166	0.00044	CbGpPWpGaD
Paricalcitol—Pruritus—Doxorubicin—urinary bladder cancer	0.000166	0.000345	CcSEcCtD
Paricalcitol—Vomiting—Epirubicin—urinary bladder cancer	0.000161	0.000335	CcSEcCtD
Paricalcitol—Nausea—Methotrexate—urinary bladder cancer	0.000161	0.000335	CcSEcCtD
Paricalcitol—Diarrhoea—Doxorubicin—urinary bladder cancer	0.00016	0.000334	CcSEcCtD
Paricalcitol—Rash—Epirubicin—urinary bladder cancer	0.000159	0.000333	CcSEcCtD
Paricalcitol—Dermatitis—Epirubicin—urinary bladder cancer	0.000159	0.000332	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—GPX1—urinary bladder cancer	0.000159	0.000421	CbGpPWpGaD
Paricalcitol—Headache—Epirubicin—urinary bladder cancer	0.000158	0.000331	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—ERCC2—urinary bladder cancer	0.000156	0.000414	CbGpPWpGaD
Paricalcitol—Dizziness—Doxorubicin—urinary bladder cancer	0.000155	0.000323	CcSEcCtD
Paricalcitol—VDR—Generic Transcription Pathway—MYC—urinary bladder cancer	0.000152	0.000402	CbGpPWpGaD
Paricalcitol—Nausea—Epirubicin—urinary bladder cancer	0.00015	0.000313	CcSEcCtD
Paricalcitol—Vomiting—Doxorubicin—urinary bladder cancer	0.000149	0.00031	CcSEcCtD
Paricalcitol—Rash—Doxorubicin—urinary bladder cancer	0.000148	0.000308	CcSEcCtD
Paricalcitol—Dermatitis—Doxorubicin—urinary bladder cancer	0.000147	0.000308	CcSEcCtD
Paricalcitol—Headache—Doxorubicin—urinary bladder cancer	0.000147	0.000306	CcSEcCtD
Paricalcitol—CYP24A1—Metabolism—MTHFR—urinary bladder cancer	0.000146	0.000389	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTP1—urinary bladder cancer	0.000144	0.000383	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—ESR1—urinary bladder cancer	0.00014	0.000373	CbGpPWpGaD
Paricalcitol—Nausea—Doxorubicin—urinary bladder cancer	0.000139	0.00029	CcSEcCtD
Paricalcitol—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000137	0.000363	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000135	0.000358	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—TYMS—urinary bladder cancer	0.000134	0.000356	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GSTM1—urinary bladder cancer	0.000132	0.000352	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—NCOR1—urinary bladder cancer	0.000132	0.000352	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—PPARG—urinary bladder cancer	0.000128	0.00034	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—GPX1—urinary bladder cancer	0.000127	0.000337	CbGpPWpGaD
Paricalcitol—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000126	0.000334	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—ERCC2—urinary bladder cancer	0.000125	0.000331	CbGpPWpGaD
Paricalcitol—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000124	0.000329	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—CREBBP—urinary bladder cancer	0.000123	0.000326	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PPARG—urinary bladder cancer	0.000119	0.000315	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—MTHFR—urinary bladder cancer	0.000117	0.000311	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—CREBBP—urinary bladder cancer	0.000114	0.000303	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PPARG—urinary bladder cancer	9.49e-05	0.000252	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTGS2—urinary bladder cancer	9.34e-05	0.000248	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—CREBBP—urinary bladder cancer	9.12e-05	0.000242	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	8.38e-05	0.000223	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—PTEN—urinary bladder cancer	8.15e-05	0.000216	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.95e-05	0.000211	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.95e-05	0.000211	CbGpPWpGaD
Paricalcitol—CYP24A1—Metabolism—EP300—urinary bladder cancer	7.77e-05	0.000206	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTGS2—urinary bladder cancer	7.47e-05	0.000198	CbGpPWpGaD
Paricalcitol—VDR—Gene Expression—MYC—urinary bladder cancer	7.3e-05	0.000194	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	7.27e-05	0.000193	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.54e-05	0.000174	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—PTEN—urinary bladder cancer	6.51e-05	0.000173	CbGpPWpGaD
Paricalcitol—UGT1A4—Metabolism—EP300—urinary bladder cancer	6.21e-05	0.000165	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	6.18e-05	0.000164	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	6.02e-05	0.00016	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.81e-05	0.000128	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.35e-05	0.000116	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.76e-05	9.98e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.48e-05	9.24e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.48e-05	9.24e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.38e-05	8.96e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.81e-05	7.45e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.34e-05	6.21e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.18e-05	5.78e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	2.15e-05	5.71e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	2.15e-05	5.71e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—GPX1—urinary bladder cancer	2.06e-05	5.47e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	2.02e-05	5.37e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.9e-05	5.05e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.54e-05	4.09e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.48e-05	3.93e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.21e-05	3.22e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.06e-05	2.81e-05	CbGpPWpGaD
Paricalcitol—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.01e-05	2.68e-05	CbGpPWpGaD
